Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70034 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Bruce L Daugherty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tonix Pharmaceuticals, Inc., Berkeley Heights, NJ, USA. Hauptthemen laut MEDLINE: Amitriptyline. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tonix Pharmaceuticals, Inc..
Abstract (Originalsprache)
Daily oral cyclobenzaprine hydrochloride (HCl) has provided transient benefits in fibromyalgia, a chronic pain condition. To improve this effect, we evaluated sublingual formulations designed to drive transmucosal absorption. Two open‐label studies evaluated the pharmacokinetics (PK), tolerability, and relative bioavailability of sublingual cyclobenzaprine HCl in healthy adults. In Study 1 (n = 24), three 2.8 mg sublingual formulations of cyclobenzaprine HCl containing potassium phosphate dibasic (A), sodium phosphate dibasic (B), or trisodium citrate (C) were compared to immediate release (IR) cyclobenzaprine HCl 5 mg. All sublingual formulations showed increased bioavailability (154% [A], 126% [B], and 125% [C]) and rapid absorption. Formulation A demonstrated the most favorable PK, with a ∼3 min absorption lag versus ∼37 min for oral IR, and a 783% higher dose‐normalized AUC 0‐1 . Formulation A was designated TNX‐102 SL for further development. In Study 2 (n = 16), TNX‐102 SL 2.8 and 5.6 mg exhibited dose proportionality and no food effect. Furthermore, this is the first report describing the active metabolite norcyclobenzaprine in clinical studies, showing an elimination half‐life of ∼60 h. Oral hypoesthesia and abnormal taste were the most common adverse events. These findings support TNX‐102 SL as a rapidly absorbed and efficient sublingual tablet formulation of cyclobenzaprine HCl, providing effective transmucosal delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tonix Pharmaceuticals, Inc., Berkeley Heights, NJ, USA.
- University of Tennessee Health Science Center, Memphis, TN, USA.
- Tonix Medicines, Inc, Berkeley Heights, NJ, USA.
Förderung
- Tonix Pharmaceuticals, Inc.
Zitieren
APA
Daugherty, B. L., Meibohm, B., Sullivan, G. M., Gould, E. M., & Lederman, S. (2026). Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70034
Vancouver
Daugherty BL, Meibohm B, Sullivan GM, Gould EM, Lederman S. Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70034
BibTeX
@article{Daugherty2026,
author = {Daugherty, Bruce L and Meibohm, Bernd and Sullivan, Gregory M and Gould, Errol M and Lederman, Seth},
title = {Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70034}
}
EUVIMED